8 completed, 1 terminated. 5 Phase 3, 2 Phase 4, 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 4 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Fumarates: new trials by email Literature Review of Fumarates trials Research Report on Fumarates
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod - Multiple Sclerosis, Relapsing-Remitting | Not applicable | Completed | Johns Hopkins University | 900 | 2018-05-02 | 2026-09-23 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Brodalumab, Fumaric acid esters - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 210 | 2017-11-03 | 2025-03-13 |
| A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Guselkumab, Fumaric Acid Esters - Psoriasis | Phase 3 | Completed | Janssen-Cilag G.m.b.H | 119 | 2016-12-12 | 2020-02-28 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Fumaric Acid Esters, Methotrexate, Ixekizumab - Plaque Psoriasis | Phase 3 | Completed | Eli Lilly and Company | 162 | 2016-01-20 | 2019-10-09 |
| Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis. Secukinumab, Fumaric acid - Psoriasis | Phase 3 | Completed | Novartis Pharmaceuticals | 202 | 2015-04-01 | 2017-10-27 |
| The Use of Iron Therapy for Patients With Anemia After Caesarean Section Ferinject, Ferrous fumarate, Placebo for ferrous fumarate - Postoperative Anaemia | Phase 4 | Terminated | Maastricht University Medical Center | 27 | 2015-03-02 | 2022-08-22 |
| Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate BG00012 (dimethyl fumarate), BG00012 placebo, ASA - Healthy | Phase 3 | Completed | Biogen | 173 | 2012-04-01 | 2016-06-13 |
| Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus Fumaric acid esters - Lupus Erythematosus, Cutaneous | Phase 2 | Completed | University Hospital Muenster | 11 | 2011-07-01 | 2014-02-28 |
| Fumaric Acid Versus Fumaric Acid Plus Narrow Band Type B Ultraviolet (UVB) for Psoriasis Full Body UV Therapy System UV 7002 plus fumaric acid esters, Fumaric acid esters - Plaque Psoriasis | Phase 3 | Completed | Medical University of Vienna | 30 | 2011-04-01 | 2014-05-12 |
Psoriasis (2) · Anemia (1) · Lupus Erythematosus, Cutaneous (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Biogen (1) · Eli Lilly and Company (1) · Janssen-Cilag G.m.b.H (1) · Johns Hopkins University (1) · LEO Pharma (1) · Maastricht University Medical Center (1) · Medical University of Vienna (1) · Novartis Pharmaceuticals (1) · University Hospital Muenster (1)
Germany (5) · United States (2) · Austria (1) · Netherlands (1)
Adrian Tanew, Prof. Dr. (1) · Annegret Kuhn, Prof. Dr. (1) · Ellen M. Mowry, MD, MCR (1) · Roy Kruitwagen (1) · Scott D. Newsome, DO (1)
PMID 25999183, PMID 31376153, PMID 38654416
2016 (2), 2015 (1)